The mechanism by which curcumin inhibits gastrointestinal tumorigenesis appears to be similar to that of sulindac, a NSAID chemopreventive agent which is highly effective in causing regression of polyps in familial polyposis patients. However, the advantage of curcumin is that it is a safe dietary component, with minimal to no toxic affects, unlike sulindac. Both curcumin and sulindac stimulate p21 expression, cell cycle arrest and apoptosis, which are likely fundamental to their mechanisms of action. This is related to, but distinctly different from, mechanisms we have investigated underlying the effect of short chain fatty acids on apoptosis of colonic epithelial cells, which also involves mitochondrial function as a critical event in the entry of cells into this pathway. The goal of this application is to determine in detail the molecular and cellular events responsible for the mechanism of action of curcumin, and to compare that to sulindac, an established, effective chemopreventive agent. We will do this both in colonic carcinoma cells in culture, and in novel mouse genetic models we have available. Studies will focus on components of the cell cycle machinery (eg. P21/waf1/cip1, cyclin D1 levels and activity) and how they are related to release of cytochrome C from the mitochondria, the dissipation of the mitochondrial membrane potential, and cleavage of caspase-3 in the apoptotic pathway. These preclinical data on mechanism and efficacy of curcumin will help determine the nature of future clinical intervention studies with curcumin: if the mechanisms appear identical to that by which sulindac functions, then a clinical study design in which curcumin is compared to sulindac, or other NSAIDs would be warranted. On the other hand, differences in mechanism could suggest a study design in which curcumin was combined with sulindac or to other NSAIDs in a prevention trial to test whether the two agents give additive, or synergistic, effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA077552-01
Application #
2597617
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1998-05-01
Project End
2002-02-28
Budget Start
1998-05-01
Budget End
1999-02-28
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Montefiore Medical Center (Bronx, NY)
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10467
Dadachova, E; Bouzahzah, B; Zuckier, L S et al. (2002) Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 29:13-8
Hawcroft, Gillian; D'Amico, Mark; Albanese, Chris et al. (2002) Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23:107-14
Fu, Maofu; Wang, Chenguang; Wang, Jian et al. (2002) Acetylation in hormone signaling and the cell cycle. Cytokine Growth Factor Rev 13:259-76
Amanatullah, D F; Zafonte, B T; Pestell, R G (2002) The cell cycle in steroid hormone regulated proliferation and differentiation. Minerva Endocrinol 27:7-20
Mariadason, J M; Bordonaro, M; Aslam, F et al. (2001) Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 61:3465-71
Wang, C; Fu, M; D'Amico, M et al. (2001) Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 21:3057-70
Yang, W; Velcich, A; Mariadason, J et al. (2001) p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res 61:6297-302
D'Amico, M; Hulit, J; Amanatullah, D F et al. (2000) The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 275:32649-57
Bouzahzah, B; Fu, M; Iavarone, A et al. (2000) Transforming growth factor-beta1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo. Cancer Res 60:4531-7
Amanatullah, D F; Reutens, A T; Zafonte, B T et al. (2000) Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 5:D372-90

Showing the most recent 10 out of 12 publications